Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review.
- VernacularTitle:前胡提取物角型吡喃骈香豆素对U266细胞增殖和凋亡的影响
- Author:
Xing SUN
1
;
Bin XU
1
;
Yufu LI
1
;
Jianwei DU
1
;
Lihua DONG
1
;
Xue GAO
1
;
Gangping LI
1
;
Xudong WEI
1
;
Yongping SONG
1
Author Information
- Publication Type:Journal Article
- MeSH: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; diagnosis; drug therapy; pathology; China; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; diagnosis; drug therapy; pathology; Neoplasm Recurrence, Local; Prednisone; Prognosis; Retrospective Studies; Vincristine
- From: Chinese Journal of Hematology 2015;36(10):853-857
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluateclinical features, treatment and outcomes of patients diagnosed with primary breast diffuse large B-cell lymphoma（DLBCL）.
METHODSClinical data were analyzed for all patients diagnosed with primary breast DLBCL（n=21）. Kaplan-Meier method was used to estimate 5- year overall survival（OS）rate, and the difference was compared by Log- rank test.
RESULTSThe 21 cases of patients with primary breast DLBCL were all female with median age at diagnosis as 48 years （range 21-64 years）. 13 patients had International Prognostic Index（IPI）of 0, 6 IPI 1, and 2 IPI 2. The 5- year OS rates of CHOP/R- CHOP and R±DICE after R±EPOCH groups were 40.0% and 72.2% , respectively（P=0.035）. The central nervous system relapse rate of CHOP/R-CHOP and R±DICE after R± EPOCH groups were 16.7% and 6.7%（P=0.500）, respectively. The 5- year OS rates of patients with primary breast DLBCL staging Ⅱ E-Ⅲ E and Ⅰ E were 21.4% and 83.3% , respectively（P=0.025）.
CONCLUSIONPrimary breast DLBCL was rare. The patients of primary breast DLBCL with chemotherapy regimen of R±DICE after R±EPOCH might have a better prognosis and lower relapse rate of central nervous system; the primary breast DLBCL patients staging ⅡE-ⅢE might have a poor prognosis.
